The effect of crosstalk between mTOR and novel pathways on the treatment of non-alcoholic fatty liver-related hepatocellular carcinoma is also of great significance for the treatment of NAFLD-related hepatocellular carcinoma in the future, which may provide a reference for the development of new mTOR inhibitors. This evidence concerns the gene MTOR and metabolic dysfunction-associated steatotic liver disease.